Jubilant Pharmova Limited · NSE:JUBLPHARMA
Jubilant Pharmova — Q2 FY22 Earnings Presentation
19 slides from Jubilant Pharmova's earnings presentation, Oct 22, 2021
Slide 1: Financial Results Quarter Ended September 30, 2021
Financial Results Quarter Ended September 30, 2021
Slide 2: Conference Call Details
Conference Call Details Date : October 22, 2021 Time : 05:00 pm IST +91 22 6280 1141 Primary Number +91 22 7115 8042 USA: 1 866 746 2133 UK: 0 808 101 1573 Toll Free Number Singapore: 800 101 2045 Hong Kong: 800 964 448 Replay: October 22 to October 29, 2021 Dial-in: +91 22 7194 5757/ +91 22 6663 57
Slide 3: Chairmen's Message
Chairmen’s Message Jubilant Pharmova Q2 and H1 FY22 1,2 Q2'FY21 Q2'FY22 H1' FY21 H1' FY22 Particulars Total Revenue from Operations 1,591 1,657 2,747 3,292 Reported EBITDA 353 344 536 723 Reported EBITDA margin (%) 22.2% 20.8% 19.5% 22.0% Profit After Tax 147 143 182 303 PAT margin (%) 9.2% 8.6% 6.6
Slide 4: Q2'FY22 Results Analysis
rr—“‘—SS es JUBILANT PHARMOVA Q2'FY22 Results Analysis
Slide 5: Q2'FY22 Financial Highlights
Q2'FY22 Financial Highlights Particulars1,2 Q2'FY21 Q2'FY22 YoY (%) Revenue Revenue was at Rs 1,657 Crore versus Rs 1,591 Crore in Q2'FY21 Pharmaceuticals 1,516 1,543 2% • Pharmaceuticals revenue at Rs 1,543 Crore as compared to Rs Contract Research and Development Services 75 108 44% 1,516 Crore
Slide 6: Pharmaceuticals Segment Highlights – Q2'FY22 (1/2)
Pharmaceuticals Segment Highlights – Q2'FY22 (1/2) 1,2 Particulars Q2'FY21 Q2'FY22 YoY (%) Pharmaceuticals revenue at Rs 1,543 Crore vs. Rs 1,516 Crore in Revenue 1,516 1,543 2% Q2’FY21 Specialty Pharma 585 651 11% Specialty Pharmaceuticals3 CDMO 506 562 11% • Radiopharma business witnessed improv
Slide 7: Pharmaceuticals Segment Highlights – Q2'FY22 (2/2)
Pharmaceuticals Segment Highlights – Q2'FY22 (2/2) USFDA Inspection Details CDMO1 Facility Last Inspection • CMO business revenue grew YoY based on continued strong demand from Montreal, Radiopharma Sep, 2017 customers as well as due to COVID related deals Montreal, CMO May, 2018 • Performance of AP
Slide 8: Contract Research and Development Services – Q2'FY22
Contract Research and Development Services – Q2'FY22 1,2 Q2'FY21 Q2'FY22 YoY (%) Particulars Contract Research and Development Services business through Revenue 75 108 44% Jubilant Biosys Limited provides innovative and collaborative research and development services from world class research Repo
Slide 9: Jubilant Therapeutics: developing best-in-class precision therapies in oncology and autoimmune diseases
Jubilant Therapeutics: developing best-in-class precision therapies in oncology and autoimmune diseases State-of-the-art Proven discovery engine with structure-based drug discovery expertise and a track record Discovery of partnerships with biotech and large pharma. Rapid discovery capabilities for
Slide 10: Jubilant Therapeutics: Differentiated portfolio in oncology & autoimmune diseases
Jubilant Therapeutics: Differentiated portfolio in oncology & autoimmune diseases Licensed to 99
Slide 11: H1'FY22 Results Analysis
H1'FY22 Results Analysis 10 10
Slide 12: H1'FY22 Financial Highlights
H1'FY22 Financial Highlights Particulars1,2 H1' FY21 H1' FY22 YoY (%) Revenue Pharmaceuticals 2,612 3,085 18% Revenue was Rs 3,292 Crore versus Rs 2,747 Crore in H1'FY21 Contract Research and Development Services 132 196 49% • Pharmaceuticals revenue at Rs 3,085 Crore as compared to Rs Proprietary
Slide 13: Pharmaceuticals Segment Highlights – H1'FY22
Pharmaceuticals Segment Highlights – H1'FY22 1,2 Geography Wise Revenue Particulars H1' FY21 H1' FY22 YoY (%) Particulars H1' FY21 H1' FY22 YoY (%) Revenue 2,612 3,085 18% India 113 228 102% Specialty Pharma 1,119 1,284 15% North America 2,118 2,451 16% CDMO 786 1,036 32% Generics 707 765 8% Europe
Slide 14: Contract Research and Development Services – H1'FY22
Contract Research and Development Services – H1'FY22 1,2 H1' FY21 H1' FY22 YoY (%) Particulars Contract Research and Development Services business through Revenue 132 196 49% Jubilant Biosys Limited provides innovative and collaborative Reported EBITDA 38 70 81% research and development services f
Slide 15: Debt Profile
Debt Profile Particulars1 31-03-21 30-06-21 30-09-21 Gross Debt Long Term 2,580 2,630 2,635 Short Term 20 0 91 Total 2,600 2,630 2,726 Cash & Equivalent 671 937 863 Net Debt (before Fx Adjustment) 1,928 1,694 1,863 QoQ Change -235 169 Change in debt on account of Fx rate -43 -39 difference from 31-M
Slide 16: Business outlook
Business outlook Pharma: In radiopharma, we continue to build a long term pipeline of radiopharmaceuticals and are executing a turnaround plan of radiopharmacies. Medium-long term outlook remains robust. Allergy business well placed to grow strongly with healthy margins over the medium term. We ex
Slide 17: Appendix
JUBILANT PHARMOVA Appendix 16
Slide 18: Income Statement – Q2 & H1 FY22
Income Statement – Q2 & H1 FY22 Particulars1,2 Q2'FY21 Q2'FY22 YoY (%) H1'FY21 H1'FY22 YoY (%) Total Revenue from Continuing Operations Pharmaceuticals 1,516 1,543 2% 2,612 3,085 18% Contract Research and Development Services 75 108 44% 132 196 49% Proprietary Novel Drugs 0 2 - 4 2 - Unallocable Cor
Slide 19: For more information
For more information For Investors: Vineet V Mayer Siddharth Rangnekar Ph: +91 120 436 1103 CDR India E-mail: vineet.mayer@jubl.com Ph: +91 +91 9769919966 E-mail: siddharth@cdr-india.com For Media: Sudhakar Safaya Clayton Dsouza Ph: +91 120 436 1062 Madison Public Relations E-mail: sudhakar.safaya@j